HLS Therapeutics Inc (HLS) - Net Assets
Based on the latest financial reports, HLS Therapeutics Inc (HLS) has net assets worth CA$61.56 Million CAD (≈ $44.53 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$137.28 Million ≈ $99.31 Million USD) and total liabilities (CA$75.72 Million ≈ $54.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check HLS Therapeutics Inc (HLS) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$61.56 Million |
| % of Total Assets | 44.84% |
| Annual Growth Rate | 7.15% |
| 5-Year Change | -61.7% |
| 10-Year Change | 146.51% |
| Growth Volatility | 118.34 |
HLS Therapeutics Inc - Net Assets Trend (1996–2025)
This chart illustrates how HLS Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of HLS Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for HLS Therapeutics Inc (1996–2025)
The table below shows the annual net assets of HLS Therapeutics Inc from 1996 to 2025. For live valuation and market cap data, see market value of HLS Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$61.56 Million ≈ $44.53 Million |
-13.71% |
| 2024-12-31 | CA$71.34 Million ≈ $51.61 Million |
-26.98% |
| 2023-12-31 | CA$97.70 Million ≈ $70.67 Million |
-22.04% |
| 2022-12-31 | CA$125.32 Million ≈ $90.65 Million |
-22.03% |
| 2021-12-31 | CA$160.74 Million ≈ $116.27 Million |
-5.03% |
| 2020-12-31 | CA$169.25 Million ≈ $122.43 Million |
-5.02% |
| 2019-12-31 | CA$178.20 Million ≈ $128.91 Million |
+12.44% |
| 2018-12-31 | CA$158.49 Million ≈ $114.65 Million |
-12.14% |
| 2017-12-31 | CA$180.38 Million ≈ $130.49 Million |
+622.33% |
| 2016-12-31 | CA$24.97 Million ≈ $18.06 Million |
-4.05% |
| 2015-12-31 | CA$26.03 Million ≈ $18.83 Million |
-44.33% |
| 2014-12-31 | CA$46.75 Million ≈ $33.82 Million |
+15.36% |
| 2013-12-31 | CA$40.53 Million ≈ $29.32 Million |
-1.13% |
| 2012-12-31 | CA$40.99 Million ≈ $29.65 Million |
+25.89% |
| 2011-12-31 | CA$32.56 Million ≈ $23.55 Million |
-2.02% |
| 2010-12-31 | CA$33.23 Million ≈ $24.04 Million |
-7.42% |
| 2009-12-31 | CA$35.90 Million ≈ $25.97 Million |
+26.69% |
| 2008-12-31 | CA$28.33 Million ≈ $20.50 Million |
-43.44% |
| 2007-12-31 | CA$50.09 Million ≈ $36.24 Million |
+63.04% |
| 2006-12-31 | CA$30.72 Million ≈ $22.23 Million |
+2.35% |
| 2005-12-31 | CA$30.02 Million ≈ $21.72 Million |
+62.96% |
| 2004-12-31 | CA$18.42 Million ≈ $13.33 Million |
-30.94% |
| 2003-12-31 | CA$26.67 Million ≈ $19.30 Million |
+9.02% |
| 2002-12-31 | CA$24.47 Million ≈ $17.70 Million |
+0.06% |
| 2001-12-31 | CA$24.45 Million ≈ $17.69 Million |
+96.00% |
| 2000-12-31 | CA$12.48 Million ≈ $9.03 Million |
-12.28% |
| 1999-12-31 | CA$14.22 Million ≈ $10.29 Million |
+42.11% |
| 1998-12-31 | CA$10.01 Million ≈ $7.24 Million |
-40.82% |
| 1997-12-31 | CA$16.91 Million ≈ $12.23 Million |
+103.51% |
| 1996-12-31 | CA$8.31 Million ≈ $6.01 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HLS Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9570.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$255.87 Million | 415.66% |
| Other Comprehensive Income | CA$-6.67 Million | -10.83% |
| Other Components | CA$16.13 Million | 26.21% |
| Total Equity | CA$61.56 Million | 100.00% |
HLS Therapeutics Inc Competitors by Market Cap
The table below lists competitors of HLS Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cisadane Sawit Raya Pt
JK:CSRA
|
$97.30 Million |
|
Polar Capital Technology Trust
LSE:PCT
|
$97.34 Million |
|
Trinity Precision Technology Co Ltd
TWO:4534
|
$97.34 Million |
|
Mono Next Public Company Limited
BK:MONO
|
$97.37 Million |
|
NanoenTekInc
KQ:039860
|
$97.27 Million |
|
Tai Tung Communication Co Ltd
TW:8011
|
$97.23 Million |
|
OptiNose
NASDAQ:OPTN
|
$97.22 Million |
|
Aureus Greenway Holdings Inc.
NASDAQ:PUSA
|
$97.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HLS Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 71,341,000 to 61,557,769, a change of -9,783,231 (-13.7%).
- Net loss of 12,647,593 reduced equity.
- Share repurchases of 1,830,492 reduced equity.
- Other comprehensive income increased equity by 3,542,157.
- Other factors increased equity by 1,152,697.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-12.65 Million | -20.55% |
| Share Repurchases | CA$1.83 Million | -2.97% |
| Other Comprehensive Income | CA$3.54 Million | +5.75% |
| Other Changes | CA$1.15 Million | +1.87% |
| Total Change | CA$- | -13.71% |
Book Value vs Market Value Analysis
This analysis compares HLS Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.46x to 2.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | CA$1.24 | CA$4.30 | x |
| 1997-12-31 | CA$2.21 | CA$4.30 | x |
| 1998-12-31 | CA$1.04 | CA$4.30 | x |
| 1999-12-31 | CA$1.42 | CA$4.30 | x |
| 2000-12-31 | CA$1.17 | CA$4.30 | x |
| 2001-12-31 | CA$1.63 | CA$4.30 | x |
| 2002-12-31 | CA$1.29 | CA$4.30 | x |
| 2003-12-31 | CA$1.40 | CA$4.30 | x |
| 2004-12-31 | CA$0.97 | CA$4.30 | x |
| 2005-12-31 | CA$1.46 | CA$4.30 | x |
| 2006-12-31 | CA$1.39 | CA$4.30 | x |
| 2007-12-31 | CA$2.22 | CA$4.30 | x |
| 2008-12-31 | CA$1.11 | CA$4.30 | x |
| 2009-12-31 | CA$1.41 | CA$4.30 | x |
| 2010-12-31 | CA$1.43 | CA$4.30 | x |
| 2011-12-31 | CA$1.61 | CA$4.30 | x |
| 2012-12-31 | CA$2.01 | CA$4.30 | x |
| 2013-12-31 | CA$2.04 | CA$4.30 | x |
| 2014-12-31 | CA$2.41 | CA$4.30 | x |
| 2015-12-31 | CA$1.47 | CA$4.30 | x |
| 2016-12-31 | CA$1.01 | CA$4.30 | x |
| 2017-12-31 | CA$7.14 | CA$4.30 | x |
| 2018-12-31 | CA$5.88 | CA$4.30 | x |
| 2019-12-31 | CA$6.07 | CA$4.30 | x |
| 2020-12-31 | CA$5.34 | CA$4.30 | x |
| 2021-12-31 | CA$4.99 | CA$4.30 | x |
| 2022-12-31 | CA$3.86 | CA$4.30 | x |
| 2023-12-31 | CA$3.03 | CA$4.30 | x |
| 2024-12-31 | CA$2.24 | CA$4.30 | x |
| 2025-12-31 | CA$1.95 | CA$4.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HLS Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.40%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 2.23x
- Recent ROE (-20.55%) is below the historical average (2.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 83.04% | 11.57% | 3.24x | 2.21x | CA$6.07 Million |
| 1997 | 10.42% | 2.29% | 1.86x | 2.44x | CA$69.88K |
| 1998 | -66.23% | -6.54% | 3.64x | 2.78x | CA$-7.63 Million |
| 1999 | 28.64% | 4.26% | 2.55x | 2.64x | CA$2.65 Million |
| 2000 | 18.34% | 2.29% | 3.90x | 2.05x | CA$1.04 Million |
| 2001 | 11.90% | 8.75% | 1.09x | 1.24x | CA$463.61K |
| 2002 | 12.05% | 8.30% | 1.24x | 1.17x | CA$500.46K |
| 2003 | 10.83% | 3.47% | 2.01x | 1.56x | CA$220.55K |
| 2004 | -47.17% | -11.17% | 2.60x | 1.63x | CA$-10.53 Million |
| 2005 | 31.67% | 13.94% | 1.54x | 1.47x | CA$6.51 Million |
| 2006 | 4.26% | 2.64% | 1.01x | 1.60x | CA$-1.76 Million |
| 2007 | 15.16% | 7.55% | 1.29x | 1.56x | CA$2.59 Million |
| 2008 | -19.91% | -8.28% | 1.49x | 1.62x | CA$-8.47 Million |
| 2009 | 7.11% | 3.55% | 1.35x | 1.49x | CA$-1.04 Million |
| 2010 | -2.21% | -0.83% | 1.94x | 1.37x | CA$-4.06 Million |
| 2011 | 36.80% | 15.22% | 1.71x | 1.41x | CA$8.73 Million |
| 2012 | 41.15% | 14.47% | 2.35x | 1.21x | CA$12.77 Million |
| 2013 | 24.02% | 12.25% | 1.45x | 1.35x | CA$5.68 Million |
| 2014 | 27.20% | 17.21% | 1.23x | 1.29x | CA$8.04 Million |
| 2015 | -6.66% | -8.68% | 0.75x | 1.02x | CA$-4.34 Million |
| 2016 | -3.50% | -1.62% | 2.12x | 1.02x | CA$-3.37 Million |
| 2017 | -3.38% | -8.12% | 0.20x | 2.13x | CA$-24.14 Million |
| 2018 | -15.65% | -40.39% | 0.20x | 1.93x | CA$-40.65 Million |
| 2019 | -10.97% | -36.10% | 0.17x | 1.79x | CA$-37.37 Million |
| 2020 | -9.06% | -27.32% | 0.18x | 1.80x | CA$-32.26 Million |
| 2021 | -8.16% | -21.86% | 0.22x | 1.72x | CA$-29.19 Million |
| 2022 | -18.83% | -38.39% | 0.25x | 1.93x | CA$-36.13 Million |
| 2023 | -28.18% | -43.65% | 0.30x | 2.14x | CA$-37.30 Million |
| 2024 | -27.55% | -34.71% | 0.35x | 2.24x | CA$-26.79 Million |
| 2025 | -20.55% | -22.40% | 0.41x | 2.23x | CA$-18.80 Million |
Industry Comparison
This section compares HLS Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $498,584,714
- Average return on equity (ROE) among peers: -44.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HLS Therapeutics Inc (HLS) | CA$61.56 Million | 83.04% | 1.23x | $97.28 Million |
| Aurora Cannabis Inc (ACB) | $218.93 Million | -5.92% | 0.47x | $170.24 Million |
| Amotiv Limited (AOV) | $746.87 Million | -2.25% | 0.27x | $576.83 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-6.45 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $6.91 Million | -242.83% | 2.23x | $12.74 Million |
| Avant Brands Inc (AVNT) | $49.33 Million | -10.28% | 0.67x | $6.44 Million |
| Bausch Health Companies Inc (BHC) | $3.26 Billion | -73.94% | 12.36x | $1.89 Billion |
| CanadaBis Capital Inc (CANB) | $7.92 Million | -10.54% | 2.10x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $550.08 Million | -25.79% | 1.50x | $12.41 Million |
| Cipher Pharmaceuticals Inc (CPH) | $126.01 Million | 22.07% | 0.24x | $297.56 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $28.25 Million | -99.58% | 0.30x | $118.76 Million |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more